Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C

Hepatology

Volumn 42, Issue 1, 2005, Pages 63-71

  Hézode, Christophe ^a   Roudot Thoraval, Françoise ^a   Nguyen, Son ^a   Grenard, Pascale ^a   Julien, Boris ^a   Zafrani, Elie Serge ^a   Pawlostky, Jean Michel ^a   Dhumeaux, Daniel ^a   Lotersztajn, Sophie ^a   Mallat, Ariane ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; TOBACCO SMOKE;

ADULT; ARTICLE; CANNABIS ADDICTION; CHRONIC HEPATITIS; COHORT ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG USE; EPIDEMIOLOGICAL DATA; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

ADULT; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; RISK FACTORS;

EID: 21344472982     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20733     Document Type: Article

References (40)

1. Wong JB, McQuillan GM, McHucchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569.
2. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coucellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. HEPATOLOGY 1999;30:1054-1058.
3. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001;32:904-909.
4. Hezode C, Lonjon I, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003; 17:1031-1037.
5. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. HEPATOLOGY 1998;27:1717-1722.
6. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
7. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. HEPATOLOGY 1997;26:485-490.
8. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340.
9. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;97:2408-2414.
10. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003;39: 1049-1055.
11. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-842.
12. Hezode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003;52:126-129.
13. Smart RG, Ogborne AC. Drug use and drinking among students in 36 countries. Addict Behav 2000;25:455-460.
14. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003;74:486-496.
15. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4:873-884.
16. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3:745-755.
17. Grenard P, Julien B, Tran Van Nhieu J, Li L, Ledent C, Mallat A, et al. Reduced liver fibrosis in CB1 receptor knock-out mice [Abstract]. J Hepatol 2004;40(Suppl 1):8.
18. Julien B, Grenard P, Teixeira-Clerc F, Tran-Van-Nhieu J, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid CB2 receptor in the liver. Gastroenterology 2005; 128:742-755.
19. Lotetsztajn S, Gtenard P, Julien B, Mallat A. Hepatic fibrosis: moleculat mechanisms and drug targets. Ann Rev Pharmacol Toxicol 2005;45:605-628.
20. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. HEPATOLOGY 1998;27:1730-1735.
21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
22. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. HEPATOLOGY 1994;20:15-20.
23. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001;34:730-739.
24. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. HEPATOLOGY 2004;39:826-834.
25. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and Steatosis. HEPATOLOGY 1999;29:1215-1219.
26. Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver fibrosis is not associated with Steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638-1643.
27. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004;53:406-412.
28. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY 2001;33:1358-1364.
29. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. HEPATOLOGY 2002;36:S47-S56.
30. Pessione F, Ramond MJ, Njapoum C, Duchatelle V, Degott C, Erlinger S, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. HEPATOLOGY 2001;34:121-125.
31. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52:574-579.
32. Bruden DL, McMahon BJ, Hennessy TW, Christensen CJ, Homan CE, Williams JL, et al. Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera. Am J Gastroenterol 2004;99:1517-1522.
33. Bauman A, Phongsavan P. Epidemiology of substance use in adolescence: prevalence, trends and policy implications. Drug Alcohol Depend 1999; 55:187-207.
34. Adlaf EM, Paglia A, Ivis FJ, Ialomiteanu A. Nonmedical drug use among adolescent students: highlights from the 1999 Ontario Student Drug Use Survey. CMAJ 2000; 162:1677-1680.
35. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004;291:2114-2121.
36. Chen K, Kandel DB. Predictors of cessation of marijuana use: an event history analysis. Drug Alcohol Depend 1998;50:109-121.
37. Chen K, Kandel DB. The natural history of drug use from adolescence to the mid-thirties in a general population sample. Am J Public Health 1995; 85:41-47.
38. Swift W, Hall W, Copeland J. One year follow-up of cannabis dependence among long-term users in Sydney, Australia. Drug Alcohol Depend 2000; 59:309-318.
39. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122:85-93.
40. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-832.